| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
18,000,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BiomX is a clinical stage microbiome product discovery company developing products using both natural and engineered phage technologies designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in diseases, such as inflammatory bowel disease (IBD), liver disease and cancer. Co. is is developing BX001, its lead product candidate, to modify the appearance of skin in a range of skin types, including in oily and acne-prone skin. BX002 is Co.'s therapeutic phage product candidate designed to treat IBD. BX003 is Co.'s therapeutic phage product candidate targeting bacteria associated with primary sclerosing cholangitis, an inflammatory liver disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
35,258 |
| Total Sell Value |
$0 |
$0 |
$0 |
$13,352 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wolfson Marina |
Chief Financial Officer |
• – – |
2025-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
68,545 |
68,545 |
|
- |
|
| Solomon Jonathan Eitan |
Chief Executive Officer |
• • – |
2025-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
126,748 |
126,748 |
|
- |
|
| Bassan Merav |
Chief Development Officer |
• – – |
2025-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
79,597 |
79,597 |
|
- |
|
| Deerfield Healthcare Innovations Fund Ii, L.p. |
*Director by Deputization |
– • – |
2025-02-27 |
4 |
OE |
$0.93 |
$657,467 |
I/I |
706,498 |
1,247,054 |
|
- |
|
| Bassan Merav |
Chief Development Officer |
• – – |
2024-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
31,749 |
31,749 |
|
- |
|
| Oron Assaf |
Chief Business Officer |
• – – |
2024-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,804 |
25,804 |
|
- |
|
| Solomon Jonathan Eitan |
Chief Executive Officer |
• • – |
2024-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
50,556 |
53,056 |
|
- |
|
| Deerfield Healthcare Innovations Fund Ii, L.p. |
*Director by Deputization |
– • – |
2024-07-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
11,766,000 |
8,938,049 |
|
- |
|
| Chimovits Erez |
10% Owner |
– – • |
2024-05-15 |
4 |
S |
$0.38 |
$9,280 |
I/I |
(24,344) |
13,773,653 |
|
- |
|
| Chimovits Erez |
10% Owner |
– – • |
2024-05-15 |
4 |
OE |
$0.24 |
$2,264,420 |
I/I |
9,280,408 |
13,797,997 |
|
- |
|
| Cystic Fibrosis Foundation |
|
– – • |
2024-05-15 |
4 |
OE |
$0.00 |
$4,778 |
D/D |
4,778,265 |
9,330,580 |
|
- |
|
| Cystic Fibrosis Foundation |
|
– – • |
2024-03-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,552,315 |
|
- |
|
| Deerfield Healthcare Innovations Fund Ii, L.p. |
*Director by Deputization |
– • • |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
I/I |
6,110,098 |
3,055,049 |
|
- |
|
| Oron Assaf |
Chief Business Officer |
• – – |
2023-11-29 |
4 |
S |
$0.34 |
$4,072 |
D/D |
(10,914) |
0 |
|
- |
|
| Oron Assaf |
Chief Business Officer |
• – – |
2023-05-22 |
4 |
B |
$0.27 |
$872 |
D/D |
3,192 |
10,914 |
2.66 |
- |
|
| Oron Assaf |
Chief Business Officer |
• – – |
2023-05-19 |
4 |
B |
$0.28 |
$1,832 |
D/D |
6,521 |
7,722 |
2.66 |
- |
|
| Oron Assaf |
Chief Business Officer |
• – – |
2023-05-18 |
4 |
B |
$0.27 |
$328 |
D/D |
1,201 |
1,201 |
2.66 |
- |
|
| Chimovits Erez |
10% Owner |
– – • |
2023-02-27 |
4 |
B |
$0.25 |
$85,260 |
I/I |
348,000 |
3,161,489 |
1.5 |
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-11-04 |
4 |
S |
$0.38 |
$567 |
I/I |
(1,501) |
2,997,025 |
|
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-11-03 |
4 |
S |
$0.37 |
$732 |
I/I |
(2,000) |
2,998,526 |
|
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-11-02 |
4 |
S |
$0.36 |
$867 |
I/I |
(2,416) |
3,000,526 |
|
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-11-01 |
4 |
S |
$0.36 |
$473 |
I/I |
(1,300) |
3,002,942 |
|
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-10-31 |
4 |
S |
$0.37 |
$1,224 |
I/I |
(3,300) |
3,004,242 |
|
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-10-28 |
4 |
S |
$0.36 |
$543 |
I/I |
(1,526) |
3,007,542 |
|
- |
|
| Ugwumba Chidozie |
Exit Form 4 - former 10% owner |
– – – |
2022-10-27 |
4 |
S |
$0.36 |
$548 |
I/I |
(1,505) |
3,009,068 |
|
- |
|
125 Records found
|
|
Page 1 of 5 |
|
|
